Ptp1b/tc-ptp dual inhibitors and protein degraders

A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, tautomer, or stereoisomer thereof:

• wherein
• each R1 and R2 independently is a residue of a carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 can be the same or different;
• R3, R4, R5, R6, R7, and R8 each independently are selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, C1-C6 alkyl, C3-C6 cycloalkyl, —C1-C6 alkylene, 4-6 membered heterocyclyl, and —C1-C6 alkylene-4-6 membered heterocyclyl, wherein C1-C6 alkyl, C3-C6cycloalkyl, and C1-C6 alkylene-4-6 membered heterocyclyl group optionally substituted on one or more available carbons by one or more substituents each independently selected from deuterium, halogen, hydroxy, C═O, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, —C1-C6-alkylene-C3-C6 cycloalkyl, C1-C6 alkyl-S(O)2—, C3-C6 cycloalkyl-S(O)2—, C1-C6 alkyl-C(O)—, C1-C6 alkoxy-C(O)—, —NH—C(O)—Ra, and —C(O)—NH—Ra, wherein Ra is C1-C6 alkyl, C3-C6 cycloalkyl and —C1-C6 alkylene-4-6 membered heterocyclyl optionally substituted on one or more available carbons by one, or more substituents each independently selected from deuterium, halogen, hydroxy, C═O, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, —C1-C6-alkylene-C3-C6 cycloalkyl, C1-C6 alkyl-S(O)2—, C1-C6 cycloalkyl-S(O)2—, C1-C6 alkyl-C(O)—, C1-C6 alkoxy-C(O)—, —NH—C(O)—Rb, and —C(O)—NH—Rb, wherein Rb is independently selected from deuterium, halogen, hydroxy, C═O, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, —C1-C6-alkylene-C3-C6 cycloalkyl, C1-C6 alkyl-S(O)2—, C3-C6 cycloalkyl-S(O)2—, C1-C6 alkyl-C(O)—, and C1-C6 alkoxy-C(O)—;
• t is 0 to 6;
• R9 is H or a group represented by formula L-B, wherein L is a linker selected from the group consisting of:
• wherein w is 1-5, x is 1-15, and each a and b is independently 0-3;
• the bond designated with an “” is attached to B;
• the bond designated with “*” represents the point of attachment of R9;
• and
• B is selected from the group B1, B2, and B3, wherein B1 is represented by a structure:
• wherein R3a is fluoro, hydrogen, or deuterium;
• B2 is represented by a structure:
• wherein R3b is fluoro, hydrogen, or deuterium;
• and
• B3 is represented by a structure:
• wherein R4 is methyl, hydrogen, or deuterium.